CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic
medicine for rare diseases, announced today that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. Dr. Gray has more
than three decades of biotechnology and healthcare experience, with a track record of successfully guiding high-potential companies
evolve to their next stage of growth. She will serve as a member of both Sarepta’s Compensation and Nominating and Corporate
Governance Committees.
"We are very pleased to welcome Dr. Gray to Sarepta’s Board of Directors. Mary Ann is deeply tenured in
providing governance and leadership for public companies as a director. With her impressive experience, coupled with her scientific
and financial acumen, Dr. Gray will make an immediate contribution to Sarepta, as we accelerate our aspiration to become one of the
most meaningful precision genetic medicine companies in the world by profoundly improving the lives of patients suffering from rare
neuromuscular diseases and other rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.
“Having watched Sarepta’s strategic transformation over the past 18 months as an outside observer, the company’s
progress has been tremendous. And yet, even with such profound progress, it is clear that Sarepta has only begun to tap its
potential. I’m excited to join Sarepta’s board and play a role at such a pivotal point in its journey,” said Dr. Gray.
Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including
the impact of therapeutics on cardiac membranes. With an early career as a scientist focused on new drug development, she
subsequently worked in equities research before becoming a senior analyst and portfolio manager. The combination of scientific and
financial expertise provides unique insights for board leadership. She most recently served on the boards of Senomyx, and Juniper
Pharmaceuticals, both companies were recently acquired; TetraLogic, a publicly-held clinical-stage biopharmaceutical company
focused on oncology and infectious diseases, Dyax Corp., a rare disease company acquired by Shire in 2016; and ACADIA
Pharmaceuticals, focused on commercialization of CNS therapies. She is President of Gray Strategic Advisors, LLC, a biotechnology
strategic planning and advisory firm.
Dr. Gray holds a Bachelor of Science degree from University of South Carolina, a Ph.D. in pharmacology from the
University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University
School of Medicine.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular
dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders,
totaling over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities,
including RNA, gene therapy and gene editing. Sarepta intends to be one of the most meaningful precision genetic medicine company
in the world, profoundly improving the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For
more information, please visit www.sarepta.com.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These
forward-looking statements include statements regarding the expectation that Dr. Gray will make an immediate contribution to
Sarepta, as it accelerates its aspiration to become one of the most meaningful precision genetic medicine companies in the world by
profoundly improving the lives of patients suffering from rare neuromuscular diseases and other rare diseases; the potential of
Sarepta; and Sarepta’s intention to be one of the most meaningful precision genetic medicine companies in the world, profoundly
improving the lives of patients suffering from rare neuromuscular diseases and other rare diseases.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s
control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its
expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S.
markets for various reasons including possible limitations of company financial and other resources, manufacturing
limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as
decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates; and
those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended
December 31, 2017 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as
other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company’s business, results of
operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces,
you are encouraged to review Sarepta's 2017 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta. We caution investors not to place
considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation
to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly
for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Jerica Pitts, 312-858-3469
jpitts@w2ogroup.com
